Related Experiment Video
Updated: Jan 20, 2026

Defining Substrate Specificities for Lipase and Phospholipase Candidates
Published on: November 23, 2016
Monoacylglycerol lipase inhibition as potential treatment for interstitial cystitis
Anu Chinnadurai1, Geraint Berger2, Ian Burkovskiy2
1Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Insights
Interstitial cystitis (IC) treatment may be improved by targeting the endocannabinoid system. Inhibiting enzymes that break down natural cannabinoids could increase levels of beneficial compounds, reducing bladder inflammation.
Area of Science:
- Urology
- Immunology
- Pharmacology
Background:
- Interstitial cystitis (IC) is a chronic bladder inflammation with unknown causes and limited long-term treatments.
- Current guidelines from EAU, AUA, and RCOG offer varied management strategies, including conservative, pharmacological, intravesical, and surgical options.
- The endocannabinoid system presents a promising therapeutic target for IC.
Purpose of the Study:
- To investigate the potential of targeting the endocannabinoid system for IC treatment.
- To explore the role of cannabinoid receptor 2 (CBR2) agonists in mitigating bladder inflammation.
- To hypothesize that inhibiting endogenous cannabinoid catabolism can enhance anti-inflammatory effects in the bladder.
Main Methods:
- Identification of CBR2 in the detrusor and urothelial sensory nerves of human bladders.
- Focus on inhibiting enzymes responsible for the breakdown of endogenous cannabinoids.
- Hypothesizing increased local concentrations of CBR2 agonists, such as 2-arachidonyl glycerol.
Main Results:
- Cannabinoid receptor 2 (CBR2) agonists have demonstrated the ability to reduce leukocyte migration.
- Activation of CBR2 inhibits the release of pro-inflammatory cytokines at inflammatory sites.
- The study hypothesizes that increased endogenous cannabinoid levels will lead to a reduced inflammatory response in the bladder.
Conclusions:
- The endocannabinoid system, particularly CBR2, offers a potential therapeutic avenue for interstitial cystitis.
- Modulating the endocannabinoid system by inhibiting catabolic enzymes may provide a novel treatment strategy for IC.
- Further research into endogenous cannabinoid modulation could lead to improved management of chronic bladder inflammation.
Abstract:
Interstitial cystitis is a chronic inflammatory condition of the urinary bladder with an unclear etiology. Currently, there are no widely accepted long-term treatment options available for patients with IC, with the European Association of Urology (EAU, 2017 guidelines), American Urology Association (AUA, 2014 guidelines), and the Royal College of Obstetricians and Gynaecologists (RCOG, 2016 guidelines) all suggesting various different conservative, pharmacological, intravesical, and surgical interventions. The endocannabinoid system represents a potential target for IC treatment and management. Activation of cannabinoid receptor 2 (CBR2) with various agonists has previously been shown to reduce leukocyte differentiation and migration, in addition to inhibiting the release of pro-inflammatory cytokines at the site of inflammation. These receptors have been identified in the detrusor and sensory nerves of the urothelium in various mammalian species, including humans. We hypothesize that by inhibiting the enzymes responsible for the catabolism of endogenous cannabinoids locally, bladder concentrations of CBR2 agonists will increase, particularly 2-arachidonyl glycerol, resulting in a diminished inflammatory response.
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Potential Energy
Inhibition of Cdk Activity
Standard Electrode Potentials

